Drug Profile
Donidalorsen - Ionis Pharmaceuticals
Alternative Names: Donidalorsen sodium; IONIS-PKK-L Rx; ISIS 721744Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Class Anti-inflammatories; Antisense oligonucleotides; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hereditary angioedema
- Phase II COVID 2019 infections
Most Recent Events
- 19 Feb 2024 Donidalorsen - Ionis Pharmaceuticals receives Orphan Drug status for Hereditary angioedema in European Union
- 22 Jan 2024 Ionis Pharmaceuticals plans to file an NDA application with the US FDA in USA for Hereditary angioedema
- 22 Jan 2024 Efficacy and adverse events data from a phase III OASIS-HAE trial in Hereditary angioedema released by Ionis Pharmaceuticasls